Type 1 Diabetes Mellitus

Metabolic·MeSH: Diabetes Mellitus, Type 1

Prevalence

200.0 / 100K

Incidence

22.0 / 100K/yr

20 drugs in development·10 companies·23 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
linagliptin	Mylan II B.V. (MYL)
saxagliptin	Mylan II B.V. (MYL)

Phase 3(5)

Drug	Company
Abatacept	Cidara Therapeutics, Inc. (CDTX)
prochymal	Mesoblast Limited (MESO)
prochymal	Mesoblast Limited (MESO)
teplizumab	Sanofi (SNY)
Teplizumab	Sanofi (SNY)

Phase 2(7)

Drug	Company
Antithymocyte Globulin	ENANTA PHARMACEUTICALS INC (ENTA)
basal insulin	MANNKIND CORP (MNKD)
bmf-219	Biomea Fusion, Inc. (BMEA)
brivekimig	Sanofi (SNY)
insulin	Sanofi (SNY)
technosphere insulin	MANNKIND CORP (MNKD)
Teplizumab	Structure Therapeutics Inc. (GPCR)

Phase 1(1)

Drug	Company
up421	Sana Biotechnology, Inc. (SANA)

Preclinical(1)

Drug	Company
sc451	Sana Biotechnology, Inc. (SANA)

Phase 4(4)

Drug	Company
Insulin	Sanofi (SNY)
Sterile Sodium Chloride	Cidara Therapeutics, Inc. (CDTX)
Teplizumab	ENANTA PHARMACEUTICALS INC (ENTA)
tirzepatide 2.5mg weekly	GH Research PLC (GHRS)

BioSniper tracks 20 drugs in development for Type 1 Diabetes Mellitus across 10 companies.

There are 23 clinical trials targeting Type 1 Diabetes Mellitus tracked by BioSniper.

The estimated prevalence of Type 1 Diabetes Mellitus is approximately 200.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.